Profil
Jane Wang is currently the Chief Scientific Officer at Apollomics, Inc. (United States).
Previously, she worked as a Principal at Pfizer Inc. and as the Vice President-Medicinal Chemistry at WuXi AppTec Co., Ltd. from 2010 to 2022.
She also served as the Chief Scientific Officer at Apollomics, Inc. from 2023 to 2024.
Dr. Wang holds a doctorate degree from the University of Maryland and an undergraduate degree from Fudan University.
Postes actifs de Jane Wang
| Sociétés | Poste | Début |
|---|---|---|
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Jane Wang
| Sociétés | Poste | Fin |
|---|---|---|
| APOLLOMICS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2024 |
| WUXI APPTEC CO., LTD. | Corporate Officer/Principal | 01/07/2022 |
| PFIZER INC. | Corporate Officer/Principal | - |
Formation de Jane Wang
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fudan University
Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical products & medical devices | Health Technology |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Health Technology |
Apollomics, Inc.
Apollomics, Inc. Financial ConglomeratesFinance Operates as a biotechnology company that focuses on development of novel medicines for cancer patients | Finance |
















